FINWIRES · TerminalLIVE
FINWIRES

TYO:4503

4 stories mentioning TYO:4503Updated just now

Every FINWIRES story that references TYO:4503, newest first.

Asia

Japan Earnings Wrap: Kao, Astellas Pharma Rise; Taiyo Yuden Declines

Japanese stocks reporting earnings traded mixed on Thursday, with gains led by cosmetics and pharmaceutical firms, while materials and electronics manufacturers declined.Kao's (TYO:4452) shares climbed 12% as attributable net income rose 32.3% to 65.7 billion yen in the first six months of the year.The cosmetics group's basic earnings per share came in higher at 72.58 yen while net sales in the first half also increased 7.8% to 871.9 billion yen.For the financial year ending Dec. 31, the company expects attributable income of 135 billion yen, net sales of 1.8 trillion yen and basic EPS of 149.21 yen.Astellas Pharma's (TYO:4503) shares gained 5% after profit attributable to owners of the parent more than doubled to 141.8 billion yen in the fiscal first quarter.The pharmaceutical company's earnings per share increased to 78.96 yen while revenue rose 27% to 640.9 billion yen in the three months ended June 30.Astellas maintained its full-year forecast, projecting an attributable profit of 300 billion yen, basic earnings per share of 167.46 yen, and revenue of 2.220 trillion yen for fiscal 2026.Taiyo Yuden (TYO:6976) shares fell nearly 12% despite returning to the black with an attributable profit of 2.50 billion yen in the first fiscal quarter.The materials and electronics company's EPS stood at 18.16 yen, while net sales jumped 11% to 93.9 billion yen.The company forecasts an attributable profit of 29 billion yen, basic EPS of 219.03 yen, net sales of 424 billion yen, and a total dividend of 90 yen per share for the fiscal year ending March 31, 2027.

TYO:4452TYO:4503TYO:6976
Asia

Astellas Pharma's Profit Soars 107% in Fiscal Q1

Astellas Pharma's (TYO:4503) profit attributable to owners of the parent more than doubled to 141.8 billion yen in the first quarter of fiscal 2026 from 68.4 billion yen a year earlier.The pharmaceutical company's earnings per share increased to 78.96 yen from 38.11 yen in the year-ago quarter, according to a Tokyo Stock Exchange filing on Wednesday.Revenue rose 27% to 640.9 billion yen in the three months ended June 30, from 505.8 billion yen a year earlier.Operating profit climbed 95% to 184.5 billion yen, while profit before tax more than doubled to 186.5 billion yen.Astellas maintained its full-year forecast, expecting attributable profit of 300 billion yen, basic earnings per share of 167.46 yen, and revenue of 2.220 trillion yen for fiscal 2026.The company also kept its annual dividend forecast unchanged at 80 yen per share, comprising an interim dividend of 40 yen and a year-end dividend of 40 yen.

TYO:4503
Asia

Pfizer, Astellas Secure FDA Nod For Bladder Cancer Drug

The U.S. Food and Drug Administration has cleared Astellas Pharma (TYO:4503) and Pfizer's bladder cancer drug combination, PADCEV and Keytruda, according to a joint release on Friday.The FDA cleared the combo for adults with severe bladder cancer to use before and after surgery.This broadens a prior November 2025 approval that limited the drug's use to cisplatin-ineligible patients with muscle-invasive bladder cancer.

TYO:4503
Asia

Astellas Pharma's Profit Surges 475% in Fiscal 2025

Astellas Pharma's (TYO:4503) profit attributable to owners of the parent soared 475% to 291.5 billion yen in fiscal year 2025 from 50.7 billion yen a year earlier.The pharmaceutical firm's earnings per share increased to 162.22 yen from 28.24 yen a year ago, according to a Tokyo bourse filing on Friday.Revenue jumped 12% to 2.139 trillion yen in the year ended March 31 from 1.912 trillion yen in the prior year.During the year, Astellas Pharma booked a 16.4 billion yen impairment loss for intangible assets related to AT132 following a halt in the gene therapy program and a redeployment of resources to ASP2957, the company said in a separate disclosure.The Japanese firm declared a final dividend of 39 yen per share for fiscal 2025, payable from June 3.For fiscal 2026, the company expects attributable profit of 300 billion yen, basic EPS of 167.46 yen, and revenue of 2.220 trillion yen.Astellas plans to pay interim and year-end dividends of 40 yen per share each for the year, which is higher than the amount paid in the year-ago period.

TYO:4503

Track with the FINWIRES app suite